Office of Intellectual Property and Sponsored Research

Licensing Opportunities in Biotechnology and Health

Biotechnology includes Bacterial Expression Systems, Protein Engineering, and Agricultural Biotechnology
Health includes Radiopharmaceuticals, Medical Diagnostics and Therapies

Bacterial Expression Systems

Technology		Description
Title	Auto Induction and Bacterial Growth Media	Summary	Describes a method for promoting auto-induction of transcription of cloned DNA in bacterial cultures. The cloned DNA is under the control of a T7 promoter whose activity can be induced by an exogenous inducer. The induction ability of the exogenous inducer is dependent on the metabolic activity of the bacterial cells in the culture.
		Competitive Advantage	Defines the parameters of a T7 bacterial expression system that allows the production of toxic target proteins.
		Applications	The method can be used to produce substantial amounts of toxic and non-toxic proteins.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	US-2004-0180423	View Patent
Patent Publication/Serial Number	US-2004-0180423	Licensing	Exclusive and non-exclusive
BSA #	02-29	Contact	C. Brakel
Technology		Description
Title	Non-inducing Media for T7 Expression Strains	Summary	Describes a method for suppressing the auto-induction of transcription of the cloned genes in T7 expression bacterial strains.
		Competitive Advantage	The non-inducing media can be used to clone and propagate bacteria strains obtained for some target proteins that are too toxic to be obtained in typical commercial media.
		Applications	Non-inducing media can be used to produce cultures for long-term maintenance of cultures for expression screening. Agar plates made with the non-inducing media allow the expression of strains cloned with DNA fragments that encode toxic target proteins.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	US-2007-0224682	View Patent
Patent Publication/Serial Number	US-2007-0224682	Licensing	Exclusive and non-exclusive
BSA #s	07-25	Contact	C. Brakel
Technology		Description
Title	T7 Expression Strains with Auto-Induction Option	Summary	Describes a method for promoting auto-induction in bacterial cells with cloned gene 1 (T7 RNA polymerase). The method provides a culture media in which one or more ingredients prevent induction of the T7 RNA polymerase gene until the bacterial cells in the culture medium deplete the concentration of the ingredients to a level that allows the induction of the T7 RNA polymerase.
		Competitive Advantage	The method eliminates the problems associated with basal unwanted induction of the T7 bacterial expression system and also eliminates the need of adding an inducer for expression during the growth period.
		Applications	The method can be used to produce substantial amounts of both non-toxic and toxic target recombinant proteins.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	US-2007-0212782	View Patent
Patent Publication/Serial Number	US-2007-0212782	Licensing	Exclusive and non-exclusive
BSA #	07-26	Contact	C. Brakel
Technology		Description
Title	Expression System for Bacteriophage T7 RNA Polymerase	Summary	Describes the bacterial T7 expression system for production of recombinant proteins under the control of the T7 RNA polymerase promoter. This enzyme can synthesize large amount of RNA transcripts in vivo and in vitro from DNA fragment cloned downstream of a T7 promoter.
		Competitive Advantage	The method allows in vivo expression of a variety of genes cloned in T7 expression systems.
		Applications	The system is used in vivo for production of recombinant proteins.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	4,952,496 5,693,489 5,869,320	View Patents
Patent Publication/Serial Number	4,952,496 5,693,489 5,869,320	Licensing	Exclusive and non-exclusive
BSA #	86-02	Contact	C. Brakel

Protein Engineering

Technology		Description
Title	Peptide Extensions to Facilitate Protein Folding and Solubility	Summary	Describes expression vectors that encode peptide extensions in-frame with a nucleic acid sequence encoding a protein or polypeptide of interest.
		Competitive Advantage	The method ameliorates problems associated with solubility and folding in high-yielding protein expression systems.
		Applications	The method can be used to produce large quantities of recombinant proteins which would otherwise be insoluble and/or are incapable of adopting to the native conformation.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	US-2003-0134352	View Patent
Patent Publication/Serial Number	US-2003-0134352	Licensing	Exclusive and non-exclusive
BSA #	01-22	Contact	C. Brakel
Technology		Description
Title	Generation of Phosphorylated Immunological Reagents	Summary	Describes a method for generating antibodies which specifically react to polypeptides phosphorylated at a specific amino acid.
		Competitive Advantage	Circumvents the problem of rapid dephosphorylation upon immunization with the phosphopeptide antigen, thereby increasing the titer of the phospho-specific antibodies being generated.
		Applications	The method can be used to generate both monoclonal and polyclonal antibodies with high titer.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,309,863	View Patent
Patent Publication/Serial Number	6,309,863	Licensing	Exclusive and non-exclusive
BSA #	98-16	Contact	C. Brakel

Agricultural Biotechnology

Technology		Description
Title	Mutant Fatty Acid Desaturase and Method for Directed Mutagenesis	Summary	Describes fatty acid desaturase mutants obtained by site directed mutagenesis which have significantly higher enzymatic activity towards substrates with fewer than 18 carbon atom chains.
		Competitive Advantage	The method can be used to alter the function of a protein by producing a library of mutants of the protein using directed mutagenesis and selecting for mutants which exhibit the desired alteration of function. In particular, provides a method to change the chain length specificity of the desaturase to produce commercially useful products such as vegetable oils rich in monounsaturated fatty acids.
		Applications	The cDNA fragments encoding these mutant desaturases can be introduced via expression vectors into prokaryotic and eukaryotic cells and can be used in the production of transgenic plants. These mutant forms of the fatty acid desaturase enzyme offer a way to manipulate the content, physical properties and commercial uses of plant-produced oils.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,686,186 7,323,335	View Patents
Patent Publication/Serial Number	6,686,186 7,323,335	Licensing	Exclusive and non-exclusive Available individually or bundled
BSA #s	02-01, 04-11	Contact	C. Brakel
Technology		Description
Title	Isoform of Castor Oleate Hydroxylase	Summary	Describes the nucleotide sequence of the gene that encodes for one of the isoforms of castor bean oleate-12-hydroxylase.
		Competitive Advantage	The method allows the biosynthesis of hydroxylated fatty acids, such as ricinoleic acid in castor seeds.
		Applications	The expression constructs that express this isoform of castor bean oleate-12-hydroxylase can be used to produce genetically modified plants that make oils, waxes and related compounds having altered hydroxylated fatty acid composition.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,974,893	View Patent
Patent Publication/Serial Number	6,974,893	Licensing	Exclusive and non-exclusive
BSA #	01-05	Contact	C. Brakel
Technology		Description
Title	Modified Acyl-ACP Desaturase	Summary	Describes a method for modifying the chain length and double bond positional specificities of soluble plant fatty acid desaturase (acyl-ACP desaturase) by modifying amino acid residues in the substrate binding channel.
		Competitive Advantage	The method can be used to understand the catalytic mechanism of other enzymes involved in the synthesis of plant seed oil.
		Applications	Understanding of the catalytic mechanism of acyl-ACP desaturase will help in the manufacture of specialized plant seed oil.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	5,705,391 5,888,790 6,100,091	View Patent
Patent Publication/Serial Number	5,705,391 5,888,790 6,100,091	Licensing	Exclusive and non-exclusive
BSA #	96-19	Contact	C. Brakel

Radiopharmaceuticals

Technology		Description
Title	Chiral Critical Clusters for Asymmetric Synthesis	Summary	Describes making and using critical clusters for asymmetric synthesis using substantially optically-pure chiral solvent molecules in a supercritical fluid.
		Competitive Advantage	The technology allows the formation of optically active chiral centers that would not form under ordinary reaction conditions.
		Applications	Include industries which make chiral compounds from non chiral reactants that can be used as an ingredient in a number of goods including personal care, pharmaceutical or cleaning products.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,486,355	View Patent
Patent Publication/Serial Number	6,486,355	Licensing	Exclusive and non-exclusive
BSA #	00-12	Contact	C. Brakel
Technology		Description
Title	Synthesis of Macrocyclic Polyaminocarboxylates for Diagnostic and Therapeutic Applications	Summary	Provides the compound 1,4,7,10-tetraazacyclododecan N,N',N",N""-tetraacetic acid (DOTA) - NHS ester and the compound 1,4,8,11-tetraazacyclotetradecane N, N', N",N""-tetraacetic acid (TETA) - NHS ester which are readily conjugated to various ligands for labeling with chelated metals.
		Competitive Advantage	The claimed compounds are useful for preparation of diagnostic imaging and therapeutic radio-ligands.
		Applications	The synthetic macrocyclic polyaminocarboxylate chelating agents can be used for stable attachment of radiometals to biological molecules such as proteins and antibodies. The conjugated chelates can be labeled with radiometals for imaging and radiotherapy.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	5,639,879	View Patent
Patent Publication/Serial Number	5,639,879	Licensing	Non-exclusive use
BSA #	95-07	Contact	C. Brakel
Technology		Description
Title	Synthesis of Macrocyclic Polyaminocarboxylates for Therapy, SPECT and PET imaging	Summary	A method for synthesis of 1,4,7 10-tetraazacyclododecane (DOTA) and 1,4,8,11-tetraazacyclotetradecane (TETA) and their N-hydroxysuccinimide esters (NHS esters) is provided. In the method cynamethylated tetranitrile precursors are hydrolyzed to form the tetraacetic acid. Reaction with N-hydroxysuccinimide forms the activated ester for use in conjunction of biological ligands.
		Competitive Advantage	The method is simple and results in high yields of the DOTA and TETA chelator compounds as well as their NHS esters. The activated esters are readily conjugated to biological molecules for use in imaging and therapeutic applications.
		Applications	The macrocyclic chelators are useful for imaging and therapy once complexed with paramagnetic of radioactive metals. Conjugated to biological ligands, they can be specifically targeted to tissues, tumors or receptors.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	5,428,156	View Patent
Patent Publication/Serial Number	5,428,156	Licensing	Non-exclusive use
BSA #	93-10	Contact	C. Brakel
Technology		Description
Title	A Simple, Rapid Method for the Preparation of Isotopically Labeled Formaldehyde	Summary	The present invention provides a simple, efficient method for production of radiolabeled formaldehyde. Methods for production of [¹¹C]-formaldehyde (¹¹CH₂O) for use in positron emission tomography (PET) are provided as are methods for synthesis of ¹³C, ¹⁴C, deuterium and tritium labeled formaldehyde.
		Competitive Advantage	Due to its versatile oxidation state, [¹¹C]-formaldehyde (¹¹CH₂O) provides a way to insert carbon-11 into compounds for use in positron emission tomography (PET) imaging through routes that are not possible using them more readily available [¹¹C]-methyl iodide (¹¹CH₃I). Lack of a simple synthetic route for its production has heretofore stymied its routine use. The present invention makes use of commercially available reagents and mild conditions to convert [¹¹C]-methyl iodide (¹¹CH₃I) to [¹¹C]-formaldehyde (¹¹CH₂O) in a 2 minute reaction. The synthesis is accomplished with little or no ¹¹C isotopic dilution. The reaction can be readily automated for incorporation into commercial PET tracer synthesis modules.
		Applications	A wide variety of synthetic routes are possible using ¹¹CH₂O, including reductive methylations, ring-closure reactions, electrophilic aromatic substitutions, Mannich-type condensations, and cyclization reactions. Thus, readily available ¹¹CH₂O enables the development and use of many new radioliglands.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	61/074,191	View Patent
Patent Publication/Serial Number	61/074,191	Licensing	Exclusive and non-exclusive
BSA #	08-25	Contact	C. Brakel

Diagnostics

Technology		Description
Title	Genomic Signature Tags	Summary	Describes a method of generating short genomic signature tags that can be sequenced to identify and quantify genomic DNAs.
		Competitive Advantage	The method provides a fast, simple and an economical approach of genome-wide finger printing of chromosomal and episomal DNAs
		Applications	Include assessing microbes in environmental and biological samples such as biofilms and potential bioterror weapons. Specific variants of the technology include analysis of methylation changes within CpG islands related to pathogenic conditions such as cancer and methods for sorting out regulatory networks.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	7,323,306	View Patent
Patent Publication/Serial Number	7,323,306	Licensing	Exclusive and non-exclusive Available individually or bundled
BSA #s	02-16, 08-01, 08-02, 08-03	Contact	C. Brakel
Technology		Description
Title	Method for Assaying Clustered DNA Damage	Summary	Describes a method for detecting and quantifying clustered DNA damages induced by exposure of the biological organism to a DNA-damaging agent.
		Competitive Advantage	The technique provides a sensitive reliable method of detecting and quantifying clustered damages in genomic DNAs or mixtures of DNAs of unknown DNA sizes. The method can be used to evaluate the biological impact of both low and high doses of radiation.
		Applications	The technology can be used for evaluating the biological impact of exposure to ionizing radiation and monitoring the efficacy of radiation and chemotherapy protocols. In addition, the assay provides a method for assessing radiation damage to humans, crops, livestock and wildlife following a nuclear mishap.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,789,022	View Patent
Patent Publication/Serial Number	6,789,022	Licensing	Exclusive and non-exclusive
BSA #	00-22	Contact	C. Brakel
Technology		Description
Title	DNA - Activated Protein Kinase Assay	Summary	Describes a method for detecting, monitoring and quantifying double-stranded DNA-activated protein kinase in biological samples.
		Competitive Advantage	Provides a simple, quantitative assay which allows one to draw meaningful correlation between the activity observed in vitro and the DNA-PK activity in vivo.
		Applications	Include the composition of a synthetic peptide which is a specific substrate for DNA-PK and an assay to identify agents that alter the in vitro and in vivo activity of DNA-PK.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,803,203	View Patent
Patent Publication/Serial Number	6,803,203	Licensing	Exclusive and non-exclusive
BSA #	01-02	Contact	C. Brakel
Technology		Description
Title	Generation of Novel Nano-Biosensors	Summary	Describes the use of a phage single-stranded DNA (ssDNA) binding protein, to develop novel nanoparticle systems whose assembly and disassembly can be controlled without heat treatment.
		Competitive Advantage	The technology permits generation of nanoparticle systems which can assemble and disassemble without thermal treatment. In addition, the method can be used to fabricate a wide array of nanoparticle systems with complex architectures and unique functional peptide domains.
		Applications	Our technology will find immediate use in the development of complex DNA based nanostructures and custom microarrays for molecular diagnostics and drug development.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	60/986000	View Patent
Patent Publication/Serial Number	60/986000	Licensing	Exclusive and non-exclusive
BSA #	08-22	Contact	K. Elcess
Technology		Description
Title	Glycosylated Carborane-Containing Metalloporphyrins	Summary	The invention provides low toxicity boronated compounds and their use in the diagnosis, visualization and treatment of tumors.
		Competitive Advantage	The glycosylation of the carborane porphyrin compounds provides enhanced solubility and potential tumor targeting specificity while reducing lipophilic behavior for use of the compound in tumor treatment particularly in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT).
		Applications	These compounds can be used in BNCT, a cancer treatment and PDT. These porphyrin compounds can be complexed to any suitable metal ion for use in MRI, SPECT, and PET imaging.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	11/746,957	View Patent
Patent Publication/Serial Number	11/746,957	Licensing	Exclusive and non-exclusive
BSA #	06-09	Contact	C. Brakel
Technology		Description
Title	Halogen-Containing Metallocarbonylporphyrins	Summary	The invention provides low toxicity halogenated, carborane-containing 5,10,15,20-tetraphenylporphyrin compounds and method of their use in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT).
		Competitive Advantage	The halogenated carborane porphyrin compounds provide a potential tumor targeting specificity in boron neutron capture therapy (BNCT) and photodynamic therapy (PDT).
		Applications	The halogenated, carborane-containing tetraphenylporphyrin compounds in methods of tumor imaging and/or diagnosis such as MRI, SPECT, or PET.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	11/689,678	View Patent
Patent Publication/Serial Number	11/689,678	Licensing	Exclusive and non-exclusive
BSA #	06-08	Contact	C. Brakel
Technology		Description
Title	Structural Model of Zn Transporters	Summary	Describes the structure of YiiP, a zinc transporter at 3.8 angstrom resolution.
		Competitive Advantage	The structure of YiiP provides an understanding of the molecular mechanism of zinc transport, and also provides an avenue for rational drug design targeting zinc homeostasis disorders.
		Applications	The structural data of YiiP can help in the development of human-bacterium chimera for structural analysis of human functional domains and to screen and design compounds useful for treating disorders mediated by zinc transporters.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	12/136,962	View Patent
Patent Publication/Serial Number	12/136,962	Licensing	Exclusive and non-exclusive
BSA #	07-21	Contact	C. Brakel
Technology		Description
Title	Fiducial Marker for Correlating Images	Summary	Describes the utilization of a fiducial marker for imaging and correlation of organic components detected by fourier transform infrared microspectroscopy (FTIRM) with trace elements detected by x-ray fluorescence (XRF).
		Competitive Advantage	The advantageous correlation allows one to obtain a detailed picture of many states, such as Parkinson's disease, Alzhemeir's disease, and cancer, by directly integrating the organic and trace metal ion distribution in the sample of interest. In addition, the fiducial marker can be used to correlate the light path of a microscope objective with an analytical instrument or modality in situations where the light path is not visible by the analytical instrument.
		Applications	This new fiducial marker is ideal fot those in the medical or research fields involved in imaging more than one aspect of a sample. This technology correlates the images of x-ray fluorescence and infrared spectroscopy and therefore can used for diagnosis and study various disease pathologies.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	60/956,522	View Patent
Patent Publication/Serial Number	60/956,522	Licensing	Exclusive and non-exclusive
BSA #	07-14	Contact	D. Price

Therapies

Technology		Description
Title	Process for the Manufacture of Sn-117m (4+) DTPA	Summary	Describes a method for the manufacture of ¹¹⁷m Sn (Sn⁴⁺) diethylene triamine pentaacetic acid (DTPA).
		Competitive Advantage	The method is simple and does not require the additional step of removing excess DTPA.
		Applications	The compound can be used for treatment of bone tumors and pain associated with bone cancer.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,541,514	View Patent
Patent Publication/Serial Number	6,541,514	Licensing	Exclusive and non-exclusive
BSA #	01-13	Contact	C. Brakel
Technology		Description
Title	Therapeutic Tin-117m Compositions	Summary	A method for inducing regression of osseous metastates in skeletal bone of a human in provided. The method involves administering a pharmaceutical composition comprising a pharmaceutically acceptable carrier and a Sn-117m (Sn⁴⁺) chelate complex.
		Competitive Advantage	The radiopharmaceutical composition defined produces minimal toxicity, but is highly effective in alleviating bone pain in cancer patients.
		Applications	The Sn-117m complexes can be used for the palliation of bone pain due to cancer and to treat osseous metastatic disease.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,517,810	View Patent
Patent Publication/Serial Number	6,517,810	Licensing	Exclusive and non-exclusive
BSA #	99-07	Contact	C. Brakel
Technology		Description
Title	Formulation of Tin-117m DTPA	Summary	Formulations of ¹¹⁷m Sn(Sn⁴⁺) DTPA complexes for delivery of higher doses of radiotin are provided as a methods of treating bone pain from cancer metastases and for treatment of bone cancer.
		Competitive Advantage	The improved ¹¹⁷m Sn(Sn⁴⁺) DTPA formulations provide greater flexibility in manufacturing and dosage of the therapeutic agent.
		Applications	The ¹¹⁷m Sn(Sn⁴⁺) DTPA can be used to treat bone pain resulting from cancer metastases and for the treatment of primary bone cancer.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,004,532	View Patent
Patent Publication/Serial Number	6,004,532	Licensing	Exclusive and non-exclusive
BSA #	97-18	Contact	C. Brakel
Technology		Description
Title	Palliation of Bone Pain using Therapeutic Tin-117m Formulations	Summary	Provides a method for alleviating bone pain due to cancer by administration of a unique pharmaceutically acceptable dosage of tin-117m(Sn-117m) stannic chelate complexes.
		Competitive Advantage	The treatment is reproducible, effective and produces minimal toxicity since it does not destroy non-cancerous tissues such as bone marrow.
		Applications	The tin-117m (Sn-117m) stannic chelate complexes can be used to lessen the bone pain due to cancer and to treat osseous metastatic disease.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	5,853,695	View Patent
Patent Publication/Serial Number	5,853,695	Licensing	Exclusive and non-exclusive
BSA #	97-01	Contact	C. Brakel
Technology		Description
Title	Human Coxsackie and Adenovirus Receptor - CAR	Summary	Describes the adenoviral binding domain and the extracellular domains of the integral human coxsackievirus and adenovirus receptor protein, CAR.
		Competitive Advantage	The technology can not only be used to engineer viral tropism and to make re-directed adenovirus for delivery of therapeutic molecules such as radioisotopes for treatment and/or imaging of tumors.
		Applications	The various human CAR gene constructs and soluble gene products described can be used in several applications including diagnostic procedures, treatment and prevention of adenoviral infections and for engineering altered virus tropism.
		Technical Details	Technical Brief
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	6,395,875 6,737,234 7,157,266 US-2007-0167610	View Patent
Patent Publication/Serial Number	6,395,875 6,737,234 7,157,266 US-2007-0167610	Licensing	Exclusive and non-exclusive Available individually or bundled
BSA #s	99-14, 98-07, 02-25, 07-03	Contact	C. Brakel
Technology		Description
Title	Carbon Nanotube - Based Drug Delivery Device	Summary	Describes tumor-targeted drug carrier system containing single walled carbon nanotubes which are simultaneously functionalized with tumor cell receptors and with a prodrug that is activated to its cytotoxic formulation within the tumor cell
		Competitive Advantage	The advantages of using a carbon nanotube-assisted drug delivery system include efficient targeting and amplification of tumor-targeting due to an enhanced permeability and retention effect of the carbon nanotube which can be efficiently loaded with the drug. The use of a non-toxic prodrug which is activated to its cytotoxic form in the tumor cells helps preserve the non-targeted normal tissue of the patient, thereby potentially reducing the side effects resulting from the therapy.
		Applications	The method can be used to develop functionalized carbon nanotube delivery system for diagnostics and therapeutic purposes.
		Technical Details	Flyer
			Press Release
			Publication
			Citations
Patent Publication/Serial Number	12/179,887	View Patent
Patent Publication/Serial Number	12/179,887	Licensing	Exclusive and non-exclusive
BSA #	08-07	Contact	K. Elcess

Last Modified: September 24, 2008
Please forward all questions about this site to: Lori-Anne Neiger